Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
ISSN: 2155-9899
José A Gómez-Puerta
PBB-B3, Brigham and Women’s Hospital. 221 Longwood Ave,
MA 02115
Tanzania
Research Article
Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease
Author(s): José A Gómez-Puerta, Sushrut S Waikar, Daniel H Solomon, Jun Liu, Graciela S Alarcón, Wolfgang C Winkelmayer and Karen H CostenbaderJosé A Gómez-Puerta, Sushrut S Waikar, Daniel H Solomon, Jun Liu, Graciela S Alarcón, Wolfgang C Winkelmayer and Karen H Costenbader
Objectives: Little is known about erythropoiesis-stimulating agents (ESAs) utilization among LN patients with incipient ESRD. We aimed to identify sociodemographic and clinical factors associated with ESA use among incident LN ESRD patients.Methods: Among all individuals age ≥18 with incident ESRD from 1995-2008 in the U.S. Renal Data System (USRDS), we identified those with systemic lupus erythematosus (ICD-9 code 710.0) as the cause of ESRD. ESA use at ESRD onset was ascertained from the Medical Evidence Report. Year of onset, age, sex, race/ethnicity, medical insurance, employment status, residential region, clinical factors and comorbidities were considered potentially associated with ESA use in multivariable-adjusted logistic regression analyses.Results: We identified 12,533 individuals with incident LN ESRD (1%.. View More»
DOI:
10.4172/2155-9899.1000179